BACKGROUND: We aimed to evaluate the factors predicting efficacy and adverse effects of enzalutamide in patients with castration-resistant prostate cancer. METHODS: We retrospectively evaluated data on 345 patients who had received enzalutamide for castration-resistant prostate cancer in 20 hospitals (Kyoto University Hospital and other satellite hospitals). Cox proportional hazards regression analysis was performed to identify factors predicting prostate-specific antigen (PSA) progression after enzalutamide treatment and logistic regression analysis for those associated with development of adverse effects. RESULTS: PSA titers decreased by >50 % in 197 patients (57 %). The median PSA progression free survival was 163 days. Gleason score >8 (HR 2.078, 95 % CI 1.37-3.153, P = 0.00058), performance status ≥1 (HR 2.292, 95 % CI 1.463-3.592, P = 0.000296), presence of bone metastasis (HR 1.774, 95 % CI 1.019-3.090, P = 0.0429), visceral metastasis (HR 2.127, 95 % CI 1.215-3.722, P = 0.00823), previous steroid treatment (HR 1.780, 95 % CI 1.207-2.626, P = 0.00361) and docetaxel treatment (HR 1.602, 95 % CI 1.051-2.442, P = 0.0284) significantly predicted the efficacy of enzalutamide. Adverse effects, including fatigue or appetite loss, occurred in 169 patients (49 %), 48 (18 %) of whom stopped enzalutamide. Age >75 years (HR 1.980, 95 % CI 1.270-3.09, P = 0.00246) and lower enzalutamide dose (HR 0.437, 95 % CI 0.255-1.270, P = 0.00249) were significantly associated with development of adverse effects. CONCLUSIONS: Enzalutamide treatment is effective in patients with castration-resistant prostate cancer with low Gleason scores, good performance status, without bone or visceral metastasis and no prior steroid or docetaxel treatment. Lower doses of enzalutamide decrease the incidence of adverse effects, especially in older patients.
BACKGROUND: We aimed to evaluate the factors predicting efficacy and adverse effects of enzalutamide in patients with castration-resistant prostate cancer. METHODS: We retrospectively evaluated data on 345 patients who had received enzalutamide for castration-resistant prostate cancer in 20 hospitals (Kyoto University Hospital and other satellite hospitals). Cox proportional hazards regression analysis was performed to identify factors predicting prostate-specific antigen (PSA) progression after enzalutamide treatment and logistic regression analysis for those associated with development of adverse effects. RESULTS:PSA titers decreased by >50 % in 197 patients (57 %). The median PSA progression free survival was 163 days. Gleason score >8 (HR 2.078, 95 % CI 1.37-3.153, P = 0.00058), performance status ≥1 (HR 2.292, 95 % CI 1.463-3.592, P = 0.000296), presence of bone metastasis (HR 1.774, 95 % CI 1.019-3.090, P = 0.0429), visceral metastasis (HR 2.127, 95 % CI 1.215-3.722, P = 0.00823), previous steroid treatment (HR 1.780, 95 % CI 1.207-2.626, P = 0.00361) and docetaxel treatment (HR 1.602, 95 % CI 1.051-2.442, P = 0.0284) significantly predicted the efficacy of enzalutamide. Adverse effects, including fatigue or appetite loss, occurred in 169 patients (49 %), 48 (18 %) of whom stopped enzalutamide. Age >75 years (HR 1.980, 95 % CI 1.270-3.09, P = 0.00246) and lower enzalutamide dose (HR 0.437, 95 % CI 0.255-1.270, P = 0.00249) were significantly associated with development of adverse effects. CONCLUSIONS:Enzalutamide treatment is effective in patients with castration-resistant prostate cancer with low Gleason scores, good performance status, without bone or visceral metastasis and no prior steroid or docetaxel treatment. Lower doses of enzalutamide decrease the incidence of adverse effects, especially in older patients.
Entities:
Keywords:
Adverse effect; Efficacy; Enzalutamide; Predicting factors; Prostate cancer
Authors: Emmanuel S Antonarakis; Changxue Lu; Hao Wang; Brandon Luber; Mary Nakazawa; Jeffrey C Roeser; Yan Chen; Tabrez A Mohammad; Yidong Chen; Helen L Fedor; Tamara L Lotan; Qizhi Zheng; Angelo M De Marzo; John T Isaacs; William B Isaacs; Rosa Nadal; Channing J Paller; Samuel R Denmeade; Michael A Carducci; Mario A Eisenberger; Jun Luo Journal: N Engl J Med Date: 2014-09-03 Impact factor: 91.245
Authors: Howard I Scher; Karim Fizazi; Fred Saad; Mary-Ellen Taplin; Cora N Sternberg; Kurt Miller; Ronald de Wit; Peter Mulders; Kim N Chi; Neal D Shore; Andrew J Armstrong; Thomas W Flaig; Aude Fléchon; Paul Mainwaring; Mark Fleming; John D Hainsworth; Mohammad Hirmand; Bryan Selby; Lynn Seely; Johann S de Bono Journal: N Engl J Med Date: 2012-08-15 Impact factor: 91.245
Authors: Andrew J Armstrong; Mario A Eisenberger; Susan Halabi; Stephane Oudard; David M Nanus; Daniel P Petrylak; A Oliver Sartor; Howard I Scher Journal: Eur Urol Date: 2011-11-12 Impact factor: 20.096
Authors: Ian F Tannock; Ronald de Wit; William R Berry; Jozsef Horti; Anna Pluzanska; Kim N Chi; Stephane Oudard; Christine Théodore; Nicholas D James; Ingela Turesson; Mark A Rosenthal; Mario A Eisenberger Journal: N Engl J Med Date: 2004-10-07 Impact factor: 91.245
Authors: Charles J Ryan; Arturo Molina; Jinhui Li; Thian Kheoh; Eric J Small; Christopher M Haqq; Russell P Grant; Johann S de Bono; Howard I Scher Journal: J Clin Oncol Date: 2013-07-01 Impact factor: 44.544
Authors: Vivek K Arora; Emily Schenkein; Rajmohan Murali; Sumit K Subudhi; John Wongvipat; Minna D Balbas; Neel Shah; Ling Cai; Eleni Efstathiou; Chris Logothetis; Deyou Zheng; Charles L Sawyers Journal: Cell Date: 2013-12-05 Impact factor: 41.582
Authors: O B Goodman; T W Flaig; A Molina; P F A Mulders; K Fizazi; H Suttmann; J Li; T Kheoh; J S de Bono; H I Scher Journal: Prostate Cancer Prostatic Dis Date: 2013-10-01 Impact factor: 5.554